Send your comments and tips to email@example.com
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Dr. Flea's blog
Nurse at small
Your Child's Health Blog
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
« Lander wins honor from biomolecular group | Main | Today's Globe: Travaglini offer, autopsies, insomnia pills, handgun surcharge, psychiatric hospital funds, college substance abuse, weekend heart attacks, Texas HPV vaccine, healthcare advocate »
Wednesday, March 14, 2007
Soros grant to help Boston groups battle drug-resistant TB
By John Donnelly, Globe Staff
Investor and philanthropist George Soros today announced a $3 million grant to Boston-based Partners in Health and Brigham and Women's Hospital in hopes of curbing the spread of extremely drug-resistant strains of tuberculosis in the small African nation of Lesotho.
Partners in Health, which has a decade of experience in treating drug-resistant TB in Haiti, Peru, and Russia, hopes that it can develop regimens to effectively battle these emerging strains of the disease. About five Brigham and Women's doctors will be involved in the project.
These new strains -- labelled XDR-TB -- have been found in 28 countries after an outbreak was reported last year in the Kwa-Zulu Natal province of South Africa. In that first documented outbreak, 52 of 53 patients identified with XDR-TB died. Since that outbreak, South Africa's death rate for those co-infected with HIV and the drug-resistant TB has been 85 percent.
"We were always afraid that multiple drug-resistant TB could meet HIV/AIDS and this is now happening," Soros said in a conference call with reporters. "It is not getting the attention it deserves."
The resistant TB has been found mainly in patients who have HIV, a virus that weakens a person's immune system and allows other diseases to flourish.
"It's a huge problem," said Dr. Paul Farmer, co-founder of Partners in Health and one of the world's leading experts on HIV and TB treatment in poor settings. "I do think there is some paralysis" in addressing the issue, he added.
But Farmer and Dr. Jim Yong Kim, another co-founder of Partners in Health and the former HIV/AIDS director at the World Health Organization, said they believed that the Soros gift would help spark both other funding and lead to a way of treating XDR-TB.
Kim said he hopes that the research in Lesotho -- a mountainous country surrounded completely by South Africa -- will lead to treatment guidelines in a year's time for people who have both HIV and XDR-TB. He said the process of developing treatment guidelines normally takes between three and five years.
Tuberculosis can be passed by coughing or sneezing to those in close proximity. Roughly 8 million people contract the disease every year, and an estimated 2 million die annually, including many who have AIDS. Kim said that an estimated 500,000 people worldwide have multiple drug-resistant TB, and that number could jump to 1.5 million by 2015, including many cases of XDR-TB.
"We need to get ahead of this problem," Kim said, adding that if the world didn't, it could return to "the pre-antibiotic era of TB control," with no effective medication for many patients.